Avesta's approach involves working with patients' mental health providers to tailor treatments to individual needs.
Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...
CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
Elon Musk's chaotic appearance at CPAC on Thursday caused Google searches for the phrase "is Elon Musk on drugs" to spike the ...
The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...
Detailed price information for Neuronetics Inc (STIM-Q) from The Globe and Mail including charting and trades.